financetom
Business
financetom
/
Business
/
Right time for Akasa Air to take advantage of market recovery, says Boeing India’s Salil Gupte
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Right time for Akasa Air to take advantage of market recovery, says Boeing India’s Salil Gupte
Nov 19, 2021 12:38 PM

The year is ending on a good note for Boeing India. Their Max aircraft is all set to regain skies after nearly three years of grounding. Boeing has also inked agreement with India's youngest airline Akasa Air for 72 Max airplanes.

Speaking to CNBC-TV18, Salil Gupte, the President of Boeing India, said, “We believe that the market here is recovering. You saw just a few weeks ago, on a Sunday, the passenger footfall surpassed the equivalent level of 2019, pre-COVID. That is an indicator that this market is going to recover as strongly as we thought, even with the second wave, and therefore a start-up carrier like Akasa Air is coming in, in an ideal time to take advantage of that recovery.”

Read Here: Sourcing from India to grow beyond $1 billion, says Boeing India Chief

On full recovery of domestic as well as in international trave,l he said, “International will take another 18 to 24 months past domestic, but domestic is much more in control of individual countries as we have seen in India with the more rapid recovery. That is why we have always said that domestic will be 18 to 24 months ahead of international.”

Also Read: Rakesh Jhunjhunwala-backed Akasa Air inks pact to buy CFM engines worth $4.5 bn for its Boeing planes

(Edited by : Aditi Gautam)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FOCUS-Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat
FOCUS-Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat
Mar 17, 2025
* Trump tariff moves raise fear medicines may not be exempt * Tariffs on medicines will hurt Trump healthcare aims, industry says * Europe, U.S. have interconnected supply chains for medicines * Medicines have long been spared from trade wars due to likely patient harm By Maggie Fick LONDON, March 18 (Reuters) - Drugmakers are urging the Trump administration and...
'Bullying' claims and China scrutiny ramp up pressure on CK Hutchison
'Bullying' claims and China scrutiny ramp up pressure on CK Hutchison
Mar 17, 2025
* Hong Kong leader says opposes use of coercion in trade * US President Trump has hailed CK Hutchison ( CKHUF ) ports deal * Chinese authorities have started looking into sale -Bloomberg * CK Hutchison ( CKHUF ) shares fall as much as 4.9% (Recasts, adds details throughout) By Clare Jim HONG KONG, March 18 (Reuters) - Hong Kong...
BRIEF-Grab Is Said To Move Forward With Talks To Acquire Rival GoTo - Bloomberg News
BRIEF-Grab Is Said To Move Forward With Talks To Acquire Rival GoTo - Bloomberg News
Mar 17, 2025
March 18 (Reuters) - GoTo Gojek Tokopedia PT Tbk : * GRAB IS SAID TO MOVE FORWARD WITH TALKS TO ACQUIRE RIVAL GOTO - BLOOMBERG NEWS Source text: https://tinyurl.com/2e6fu2ma Further company coverage: ...
Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat
Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat
Mar 17, 2025
LONDON (Reuters) -Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff wars, hoping to avert price spikes on top-selling medicines made in Europe from Novo Nordisk's Wegovy for weight loss to Merck's ( MRK ) cancer immunotherapy Keytruda. In conversations with U.S. officials, the pharmaceutical industry argued that tariffs on the EU...
Copyright 2023-2026 - www.financetom.com All Rights Reserved